News Release

Research Article Cites Cleanascite™ for Proteomic Screening of Novel Biomarkers in Bile

MONMOUTH JUNCTION, NJ, March 22, 2023 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their lipid clearance sample preparation technology for proteomic screening of novel biomarkers in bile fluid.

The citation is:

Qin WH, Liu JT, Wang SP, Yang ZS, Wang KK, Hu B. Antibody array-based proteomic screening of novel biomarkers in malignant biliary stricture. Cancer Biomark. 2022;33(3):359-368. doi: 10.3233/CBM-210095. PMID: 34542063.

Distinguishing between benign and malignant bile duct strictures has long been a diagnostic challenge in clinical practice. Bile is the immediate biofluid for malignant tumors involving the bile duct, so tumor-related proteins may become detectable in bile rather than serum, especially during earlier stages of disease. Thus the molecular diagnosis of malignant biliary stricture using biomarkers in bile has been the subject of intensive investigation. This study aimed to discover novel biomarkers in bile to improve the diagnostic accuracy of malignant biliary strictures. Protein profiles of the bile were analyzed with a semi-quantitative human antibody array of 440 proteins. The article states “…bile was collected upstream from the biliary stricture, then mixed with PBS containing 0.1% Tween 20 and a protease inhibitor cocktail …, the supernatant was mixed with Cleanascite™ (Biotech Support Group, NJ, USA) to remove lipids. The article concludes that twenty proteins were found differentially expressed in malignant versus benign biliary strictures, 6 of which were identified by Venn diagram analysis to be up-regulated regardless of the location of biliary strictures. Lipocalin-2, P-cadherin and CA19-9 were identified as a group of markers best distinguishing malignant from benign strictures. 

“In this important clinical problem, it is great to see that Cleanascite™ efficiently removed lipids from bile fluid, allowing for proteome analysis using antibody-based arrays.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords

bile duct strictures, malignant biliary strictures, malignant versus benign biliary strictures, bile lipid removal, Cleanascite™,

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

For Business Development, Contact:

Matthew Kuruc 732-274-2866 mkuruc@biotechsupportgroup.com